Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03522064 | Bipolar Androgen Therapy + Carboplatin in mCRPC(HiTeCH) | recruiting | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04946370 | Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT00951535 | A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17 | active not recruiting | Phase 2 | 251 | Cancer Trials IrelandNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06347705 | A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06615752 | Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | recruiting | Phase 1 / Phase 2 | 99 | Charles Drew University of Medicine and ScienceOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | active not recruiting | Phase 2 | 8 | University of WashingtonOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04337580 | Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer(FASN) | recruiting | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04842890 | Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer | active not recruiting | Phase 2 | 61 | The New York Proton CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06190899 | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 54 | Celcuity IncINDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT06610825 | Castrate Resistant Prostate Cancer Enhertu Therapy(CaRPET) | recruiting | Phase 2 | 60 | Washington D.C. Veterans Affairs Medical CenterFED | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00859781 | 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | active not recruiting | Phase 2 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer(VA STARPORT) | recruiting | Phase 2 / Phase 3 | 464 | VA Office of Research and DevelopmentFED | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)(AlphaBreak) | active not recruiting | Phase 2 | 110 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).(TATCIST) | active not recruiting | Phase 2 | 115 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07259213 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC(RAD402) | recruiting | Phase 1 / Phase 2 | 73 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03471650 | Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06244004 | FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | recruiting | Phase 2 | 125 | Northwestern UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04663997 | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | active not recruiting | Phase 2 | 200 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07073794 | Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03787680 | Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | active not recruiting | Phase 2 | 49 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05658003 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06798558 | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | recruiting | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | active not recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers(THUNDER) | recruiting | Phase 2 / Phase 3 | 493 | Cancer Research AntwerpOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476677 | Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer(ANDARP) | not yet recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | recruiting | Phase 2 | 75 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | recruiting | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07457164 | A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer | not yet recruiting | Phase 2 | 40 | Antev Ltd.INDUSTRY | 0 | Mar 12, 2026 | clinicaltrials |
| NCT03424850 | Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy | recruiting | Phase 1 / Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06437574 | Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer | recruiting | Phase 2 | 140 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06216249 | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) | recruiting | Phase 2 | 90 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02905318 | Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 19 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03808077 | The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer | active not recruiting | Phase 2 | 139 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06330805 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | recruiting | Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06463457 | Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) | active not recruiting | Phase 2 | 33 | Atish Choudhury, MDOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07182279 | Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 29 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2026source: clinicaltrials